China National Intellectual Property Administration Affirms Validity of Harbour BioMed's Patent; Infringement Lawsuit Moves Forward
On September 27, 2024, Harbour BioMed filed a patent infringement lawsuit with the Shanghai Intellectual Property Court against Biocytogen, alleging that its RenNano platform infringes Harbour BioMed's HCAb Patent. Biocytogen subsequently challenged the court's jurisdiction, first through an objection submitted to the Shanghai Intellectual Property Court on November 8, 2024, and later through an appeal to the Supreme People's Court of the People's Republic of China on March 14, 2025. On May 27, 2025, the Supreme People's Court of the People's Republic of China issued a final ruling, dismissing the appeal and affirming the jurisdiction of the Shanghai Intellectual Property Court over the infringement lawsuit. This case has now advanced to the next stage of trial.
Dr. Jingsong Wang, Founder, Chairman, and CEO of Harbour BioMed, commented: "CNIPA's decision affirms the rightful protections of the pioneering innovation and core value of Harbour BioMed's intellectual property. We have established a global patent portfolio across key markets, providing robust protection for R&D investments and proprietary innovations enabled by our Harbour Mice® platform and associated technologies. Moving forward, we will continue to leverage our patented HCAb technology to accelerate the development of transformative therapies in collaboration with global partners, ultimately bringing meaningful benefits to patients worldwide."
About Harbour BioMed
Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology. The company is building a robust and differentiated pipeline through internal R&D capabilities, strategic global collaborations in co-discovery and co-development, and selective acquisitions.
Harbour BioMed's proprietary antibody technology platform, Harbour Mice®, generates fully human monoclonal antibodies in both the conventional two heavy and two light chain (H2L2) format and the heavy chain-only (HCAb) format. Building upon HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) bispecific antibody technology enables tumor-killing effects that traditional combination therapies cannot achieve. Additionally, the HCAb-based bispecific immune cell antagonist (HBICATM) technology empowers the development of innovative biologics for immunological and inflammatory diseases. By integrating Harbour Mice®, HBICE®, and HBICATM with a single B-cell cloning platform, Harbour BioMed has built a highly efficient and distinctive antibody discovery engine for developing next-generation therapeutic antibodies. For more information, please visit www.harbourbiomed.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/china-national-intellectual-property-administration-affirms-validity-of-harbour-biomeds-patent-infringement-lawsuit-moves-forward-302482384.html
SOURCE Harbour BioMed
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
Brave dog who battled a bull earns Hambone Award® for most unusual pet story
Nationwide's 17th annual contest recognizes uncommon pet insurance claims COLUMBUS, Ohio, Aug. 20, 2025 /PRNewswire/ -- Ziya, a Belgian Malinois from northern California, who found himself in the middle of a real-life bullfight (minus the red cape), has captured the 17th annual Hambone Award® which recognizes the most unusual pet insurance claim of the year. Nationwide® presents the award annually to bring awareness to the unexpected and downright outrageous events that can happen to our pets—demonstrating how pet insurance plays an important role in protecting and caring for our companions. Ziya was adopted by a longtime dog lover named Tim. This unique pup was training to be a working dog, but his personality was better suited for companionship. Ziya quickly settled into his new role as protector of Tim's 80-acre property, showing off his tracking skills and ever watchful nature. This story begins on a quiet morning, when a routine stroll with his pet parents took a wild turn. Out of the misty fog came an unexpected guest: a loose, angry bull. Without hesitation Ziya leapt into action placing himself between the bull and his owners. While his owners escaped to safety, the bull struck Ziya in the jaw, dislodging a tooth and sending him to the emergency vet. Thanks to expert veterinary care, Ziya made a full recovery and now hopes that future walks will not involve horned adversaries. "Tim's bond with Ziya enabled them to take turns caring for each other when a bull unexpectedly joined their morning walk," said Dr. Emily M. Tincher, Chief Veterinary Officer at Nationwide. "Thanks to the care provided by Ziya's veterinary team and the protection provided by Nationwide pet insurance, this story of unexpected trauma has a happy ending!" Nationwide hosted a public vote August 5-12, 2025 to determine the most unusual pet insurance claim story and two runners-up from a field of 10 finalists. Ziya and Tim received the coveted Hambone Award trophy and a Petco gift card, the runners up will also receive Petco gift cards. The runners-up were: Duke, a lab-mix from Ohio, who swallowed an entire spatula head after licking off some peanut butter while he was staying at his dog sitter's house. Foxtrot, a Great Dane in Texas, stole a full turkey leg straight from the tongs in her owner's hands the day after Thanksgiving—and swallowed it whole. The Hambone Award was originally named after a Nationwide-insured dog who got stuck in a refrigerator and ate an entire holiday ham while waiting to be discovered. The dog was eventually found, with a licked-clean ham bone and a mild case of hypothermia. Check out the stories of all ten 2025 nominees. All nominated pets have recovered and received reimbursements for eligible veterinary expenses from Nationwide® pet insurance. To explore pet health insurance coverage for dogs, cats and many avian and exotic pets, visit About Nationwide pet insuranceWith more than 1 million actively insured pets, Nationwide is the first and one of the largest providers of pet insurance in the United States. Nationwide pet insurance plans cover dogs, cats, birds and exotic pets for multiple medical problems and conditions relating to accidents, illnesses and injuries. Medical plans are available in all 50 states and the District of Columbia. Products underwritten by Veterinary Pet Insurance Company (CA), Columbus, OH; National Casualty Company (all other states), Columbus, OH. Agency of Record: DVM Insurance Agency. All are subsidiaries of Nationwide Mutual Insurance Company. Products and discounts not available to all persons in all states. Insurance terms, definitions and explanations are intended for informational purposes only and do not in any way replace or modify the definitions and information contained in individual insurance contracts, policies or declaration pages, which are controlling. Pet owners can find Nationwide pet insurance on Instagram. For more information about Nationwide pet insurance, call 800-USA-PETS (800-872-7387) or visit About NationwideNationwide, a Fortune 100 company based in Columbus, Ohio, is one of the largest and strongest diversified financial services and insurance organizations in the United States. Nationwide is rated A+ by Standard & Poor's. An industry leader in driving customer-focused innovation, Nationwide provides a full range of insurance and financial services products including auto, business, homeowners, farm and life insurance; public and private sector retirement plans, annuities and mutual funds; excess & surplus, specialty and surety; and pet, motorcycle and boat insurance. For more information about Nationwide and Nationwide's ratings, visit or Company Ratings -- Nationwide. Subscribe today to receive the latest news from Nationwide and follow Nationwide PR on X. Nationwide, Nationwide is on your side and the Nationwide N and Eagle are service marks of Nationwide Mutual Insurance Company. © 2025 Contact:Lyndsey Kleven(614) 249-6349 KLEVEl1@ to Nationwide News View original content to download multimedia: SOURCE Nationwide Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
an hour ago
- Business Wire
Polio Vaccination Campaign Planned in Afghanistan with PharmaJet
GOLDEN, Colo.--(BUSINESS WIRE)--Please replace the release dated August 19, 2025 with the following corrected version due to multiple revisions - removing mentions of WHO and UNICEF and all operational details which are subject to national authorities and partners agreement. The updated release reads: Polio Vaccination Campaign Planned in Afghanistan with PharmaJet ® Tropis ® ID Delivery System PharmaJet has been awarded a tender to support the first large-scale implementation of intradermal (ID) polio immunization in Afghanistan. PharmaJet's award builds on the successful implementation of Tropis for ID delivery in polio vaccination campaigns in Pakistan, Nigeria, and Somalia. The use of Tropis ID in polio vaccination campaigns has improved vaccine coverage, decreased immunization program costs, and increased acceptability. PharmaJet ®, a company that strives to improve the performance and outcomes of injectables with its enabling needle-free injection technology, today announced that the WHO prequalified Tropis ID delivery system will be used to support a polio eradication campaign in Afghanistan. Poliovirus has been eliminated in most parts of the world due to widespread vaccination campaigns, but it continues to circulate in Afghanistan and Pakistan. In 2024, wild poliovirus type 1 (WPV1) transmission rose significantly in Afghanistan. The use of Tropis ID enables site-to-site immunization, a strategy where vaccination services are offered at multiple, convenient locations. Including Tropis ID fractional doses of inactivated polio vaccine (fIPV) in this immunization program supports Afghanistan's polio eradication goals to eliminate persistent virus lineages, prevent new WPV1 cases, and prevent local transmission. 'We are pleased to be supporting Afghanistan in their continued efforts to eradicate polio,' said Paul LaBarre, Senior Vice President Global Business Development, PharmaJet. 'We aim to achieve high impact in the fight against poliovirus, including increased coverage, decreased costs, and high acceptability 1 previously seen with Tropis ID delivered fIPV in Pakistan, 1 Somalia, 2 and Nigeria 3.' Refer to Instructions for Use to ensure safe injections and to review risks. *NOTE: We regret that the content of this news release on August 19, 2025 was originally published without UNICEF/WHO consent. Operational details remain subject to national authorities and partners agreement. 1 Daly, C et al, Needle-free injectors for mass administration of fractional dose inactivated poliovirus vaccine (fIPV) in Karachi, Pakistan: A survey of caregiver and vaccinator acceptability, Vaccine, Volume 38 Issue 8, 18 February, 2020, Pages 1893-1898 2 Nouh, K et al, Use of a fractional dose of inactivated polio vaccine (fIPV) to increase IPV coverage among children under 5 years of age in Somalia, Springer Nature Volume 2 article number 16 (2024) 3 Biya, O et al, Notes from the Field: House-to-House Campaign Administration of Inactivated Poliovirus Vaccine — Sokoto State, Nigeria, November 2022, CDC Morbidity and Mortality Weekly report, November 24, 2023 / 72(47);1290–1291 About PharmaJet The PharmaJet mission is to improve the performance and outcomes of injectables with our enabling technology that better activates the immune system. We are committed to helping our partners realize their research and commercialization goals while making an impact on public health. PharmaJet Precision Delivery Systems™ can improve vaccine effectiveness, allow for a preferred patient and caregiver experience, and offer a proven path to commercialization. They are also safe, fast, and easy-to-use. The Stratis ® System has U.S. FDA 510(k) marketing clearance, CE Mark, and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously. The Tropis ® System has CE Mark and WHO PQS certification for intradermal injections. They are both commercially available for global immunization programs. For more information or if you are interested in partnering with PharmaJet visit or contact PharmaJet here. Follow us on LinkedIn.
Business Wire
an hour ago
- Business Wire
CORRECTING and REPLACING Polio Vaccination Campaign Planned in Afghanistan with PharmaJet
GOLDEN, Colo.--(BUSINESS WIRE)--Please replace the release dated Aug. 19, 2025 with the following corrected version due to multiple revisions - removing mentions of WHO and UNICEF and all operational details which are subject to national authorities and partners agreement. The updated release reads: Polio Vaccination Campaign Planned in Afghanistan with PharmaJet ® Tropis ® ID Delivery System PharmaJet has been awarded a tender to support the first large-scale implementation of intradermal (ID) polio immunization in Afghanistan. PharmaJet's award builds on the successful implementation of Tropis for ID delivery in polio vaccination campaigns in Pakistan, Nigeria, and Somalia. The use of Tropis ID in polio vaccination campaigns has improved vaccine coverage, decreased immunization program costs, and increased acceptability. PharmaJet ®, a company that strives to improve the performance and outcomes of injectables with its enabling needle-free injection technology, today announced that the WHO prequalified Tropis ID delivery system will be used to support a polio eradication campaign in Afghanistan. Poliovirus has been eliminated in most parts of the world due to widespread vaccination campaigns, but it continues to circulate in Afghanistan and Pakistan. In 2024, wild poliovirus type 1 (WPV1) transmission rose significantly in Afghanistan. The use of Tropis ID enables site-to-site immunization, a strategy where vaccination services are offered at multiple, convenient locations. Including Tropis ID fractional doses of inactivated polio vaccine (fIPV) in this immunization program supports Afghanistan's polio eradication goals to eliminate persistent virus lineages, prevent new WPV1 cases, and prevent local transmission. 'We are pleased to be supporting Afghanistan in their continued efforts to eradicate polio,' said Paul LaBarre, Senior Vice President Global Business Development, PharmaJet. 'We aim to achieve high impact in the fight against poliovirus, including increased coverage, decreased costs, and high acceptability 1 previously seen with Tropis ID delivered fIPV in Pakistan, 1 Somalia, 2 and Nigeria 3.' Refer to Instructions for Use to ensure safe injections and to review risks. About PharmaJet The PharmaJet mission is to improve the performance and outcomes of injectables with our enabling technology that better activates the immune system. We are committed to helping our partners realize their research and commercialization goals while making an impact on public health. PharmaJet Precision Delivery Systems™ can improve vaccine effectiveness, allow for a preferred patient and caregiver experience, and offer a proven path to commercialization. They are also safe, fast, and easy-to-use. The Stratis ® System has U.S. FDA 510(k) marketing clearance, CE Mark, and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously. The Tropis ® System has CE Mark and WHO PQS certification for intradermal injections. They are both commercially available for global immunization programs. For more information or if you are interested in partnering with PharmaJet visit or contact PharmaJet here. Follow us on LinkedIn.
